Video

ESAs and Death Risk


 

Dr. Julia Bohlius and Dr. Andreas Engert discuss findings that cancer patients on erythropoiesis-stimulating agents are 17% more likely to die of any cause while in clinical trials. Jane MacNeil of Elsevier Global Medical News (EGMN) reports from the annual meeting of the American Society of Hematology.

Next Article: